Neurocognitive and mood side effects of cytokine/interleukin therapy (including neuroimaging, animal models of Blood Brain Barrier);
Neurotoxic and neurocognitive side effects of cancer chemotherapy (including neuroimaging, animal models, BBB);
Immune factors (molecules and cells) in neurodegeneration and autoimmune disease of CNS (including multiple sclerosis, Alzheimer’s Disease);
Molecular and functional interactions of interleukin/chemokine and neurotransmitter/neuropeptide receptors;
Biomarkers to be applied in ambulatory clinical settings to quantitate effects of cognitive and behavioral interventions, stress, and mood states on immune function and disease. These measures could include neurophysiological, neuroendocrine and immune measures in biological fluids and tissues including sweat, saliva, skin. Disease outcomes could include autoimmune or allergic diseases, inflammatory arthritis or asthma, and stress-related illnesses including hypertension and cardiovascular disease;
Fibromyalgia, Chronic Fatigue Syndrome and chronic pain syndromes: neural immune factors in pathogenesis, diagnosis and treatment of these illnesses;
Effects of hormones (neurohormones, sex hormones) and neural factors on immunity and immune mediated diseases (including arthritis, m.s., inflammatory/irritable bowel disease, septic shock, bacterial and viral infections, and antibody production for vaccine);
Infectious diseases of the CNS mediated through immune mechanisms, including acute and chronic Lyme disease and neuroAIDS;
Neural immune and neuroendocrine correlates of exposure to drugs of abuse.
Other topics as approved by the INIP Steering Committee.
The Associated Press Wednesday, April 27, 2005; 12:31 PM
ATLANTA -- The Centers for Disease Control and Prevention has started a telephone survey to identify the extent of chronic disease syndrome in Georgia.
The survey will allow the federal health agency to estimate the extent the syndrome in Georgia and in the United States, the agency said in a statement.
About 800,000 people in the United States have chronic disease syndrome or similar illnesses. Minorities and people with low incomes appear to be affected by the syndrome more often than others, the CDC said.
The survey will interview 17,000 randomly selected households in Georgia. More detailed interviews will be conducted to those who have the syndrome's symptoms, which includes a severe and debilitating fatigue, and those who appear to have the illness will be given free medical and lab evaluations.
Residents of DeKalb, Fulton, Bibb, Houston, Baldwin, Bleckley, Crawford, Jones, Macon, Monroe, Peach, Twiggs and Wilkinson counties will be interviewed for the study.
The CDC first started researching chronic disease syndrome two decades ago after investigating an outbreak of an unknown illness characterized by debilitating fatigue among residents of Incline Village, Nev. The agency has conducted a series of studies on CFS since 1988. The cause of CFS remains unknown, the CDC said.
Julie Louise Gerberding, M.D., M.P.H.April 16, 2005 Director, Centers for Disease Control and Prevention 1600 Clifton Road, N.E., Mailstop D-14 Atlanta, Georgia 30333
Dear Dr. Gerberding,
1)Please review the enclosed correspondence regarding the testing for Lyme disease, and as regards Lyme as a congenital infection.Notice that Yale Department of Pathology assessed that the cause of death of the newborn was probably brain damage from this permanent brain infection.I understand you had communicated with a Lyme patient, and said Lyme does not congenitally confer, but I do not have a signed copy of this correspondence, allegedly of your authorship.
2)The testing for Lyme disease or Lyme borreliosis or any borreliosis is deliberately off the mark, which was intended to falsely qualify these Lyme vaccines.Please see the CDC’s 1994 Dearborn Conference booklet, and you will see that my summary of the “contributions” of the invited labs was accurate, as I described to the FDA January 31, 2001.The Dearborn conference was a farce, plain and simple.Please see my explanation of how this fraud occurred on the FDA’ website, which represents part my presentation Jan 31, 2001 to the FDA in Bethesda, MD:
If you don’t have a copy of the CDC’s former criteria for Lyme disease (1990), please let me know, I will send you a copy.I gave a copy to CT AG Richard Blumenthal’s office (hand delivered).
3)It is also a certainly that Mark Klempner’s results of his 4.7 million dollar Chronic Lyme “study” was utter nonsense.Klempner himself defined chronic Lyme in 1992 (see PubMed ID 1634816)“Fibroblasts protected B. burgdorferi for at least 14 days of exposure to ceftriaxone. Mouse keratinocytes, HEp-2 cells, and Vero cells but not Caco-2 cells showed the same protective effect. Thus, several eukaryotic cell types provide the Lyme disease spirochete with a protective environment contributing to its long-term survival.”
The time has come, where we will have to demand accountability from the CDC regarding what “Lyme disease” is, and how to test for it.According to Alan Barbour, the owner of the rOspA patent for the ImmuLyme vaccine:“These tick-borne infections are notable for multiphasic antigenic variation through DNA recombinations in the case of relapsing fever, the occurrence of chronic arthritis in the case of Lyme disease, and invasion of and persistence in the brain in the case of both diseases.”
Yale University applied for a patent for borrelial flagellar antigen in 1993.Such an antibody test could be about 95% accurate for borrelioses.However, it would not have falsely qualified the bogus vaccines, Yale’s LYMErix and Alan Barbour’s ImmuLyme.“Lyme disease” is not “controversial,” it is criminal racketeering and scientific fraud.
I am requesting a valid response from you, and henceforth, 100% accountability on this “Lyme business,” from the CDC.
KMDickson,23 Garden Street, Pawcatuck, CT 06379
CC: International Lyme and Associated Diseases Society, POBOX:341461, Bethesda, MD, 20827-1461,United States Attorney General Alberto Gonzales, 950 Penn Ave NW, DC 20530
